Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020531 and Metabolites Following Oral Administration to Chinese Healthy Volunteers

Trial Profile

A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020531 and Metabolites Following Oral Administration to Chinese Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs RO 7020531 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 12 Sep 2018 Planned End Date changed from 12 Jan 2019 to 19 Jan 2019.
    • 12 Sep 2018 Planned primary completion date changed from 12 Jan 2019 to 19 Jan 2019.
    • 06 Jun 2018 Planned End Date changed from 13 Dec 2018 to 12 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top